Background/Objectives: a criticism of glycemic index (GI) is that it does not indicate the insulin response of foods (insulinemic index, II). However, it is unknown if the GI and II values of foods are equivalent in all subjects, a necessary criterion for clinical utility. We compared GI and II values in non-diabetic subjects with fasting-serum-insulin (FSI) o40 pmol/l (healthy control) or with FSI X40 pmol/l (hyper [I]) and subjects with type 2 diabetes (T2DM), and to see whether GI and II were related to the serum-glucose concentrations, insulin sensitivity, b-cell function and hepatic insulin extraction (HIE) of the subjects. Subjects/Methods: Serum-glucose, -insulin and -C-peptide responses after 50 g available-carbohydrate portions of glucose (tested three times by each subject), sucrose, instant mashed-potato, white-bread, polished-rice and pearled-barley were measured in healthy control (n ¼ 9), hyper[I] (n ¼ 12) and T2DM (n ¼ 10) subjects. Results: Food GI values did not differ significantly among the three subject groups, whereas II values were higher in T2DM (100 ± 7) than healthy controls (78 ± 5) and hyper[I] subjects (70 ± 5) (mean ± s.e.m., P ¼ 0.05). II was inversely associated with insulin sensitivity (r ¼ À0.66, Po0.0001) and positively related to fasting-and postprandial-glucose (both r ¼ 0.68, Po0.0001) and HIE (r ¼ 0.62, P ¼ 0.0002). In contrast, GI was not related to any of the biomarkers (P40.05). Conclusion: The GI is a valid property of foods because its value is similar in healthy control, hyper [I] and T2DM subjects, and is independent of subjects' metabolic status. However, II may depend upon the glycaemic control, insulin sensitivity and HIE of the subjects.
Introduction
The blood glucose raising potential of carbohydrate in foods is numerically classified as glycemic index (GI), which is the incremental area under the glycemic response curve (AUC) elicited by a 50 g available-carbohydrate portion of a food expressed as a percentage of that after 50 g glucose in the same subject (Jenkins et al., 1981) . Many foods have been tested for their GI values in healthy control or diabetic subjects (Foster-Powell et al., 2002) . As the GI values of foods are similar in healthy control and diabetic subjects (Jenkins et al., 1983 , Wolever et al., 1987 , 1988 , GI values tested in healthy control subjects can be applied in the nutritional management of diabetes (Atkinson, 2008) . However, as GI has never been tested in non-diabetic subjects with insulin resistance/hyperinsulinemia, it is unknown whether GI is valid in this population.
As hyperinsulinemia may have a role in the pathogenesis of insulin resistance and associated chronic diseases (Nilsson et al., 2003 , Takahashi et al., 2006 , a major concern about the GI concept is that it does not consider concurrent insulin response. Thus, some investigators have begun to report insulinemic index (II) (Lee and Wolever, 1998 , Miller et al., 1995 , Holt et al., 1997 . II is calculated similarly to GI in measuring the extent to which a food raises plasma insulin (Wolever et al., 1991) . However, for II to be a valid property of a food, its value should be similar in different subjects regardless of their degree of insulin sensitivity, b-cell function or glucose tolerance status. There is evidence that relative insulin responses differ in lean and obese subjects with normal glucose tolerance, subjects with impaired glucose tolerance and subjects with type 2 diabetes (T2DM) . In addition, relative insulin responses were inversely related to subjects' fasting insulin, suggesting that II may be dependent on subject's insulin sensitivity (Wolever et al., 2004) . However, these studies used mixed meals rather than individual foods and did not use standard GI methodology; thus, their results cannot be used to draw conclusions about the validity of the II values of carbohydrate foods.
Therefore, we investigated whether the GI and II values of a variety of carbohydrate foods are similar in healthy control, hyperinsulinemic and T2DM subjects, and whether metabolic status (insulin sensitivity, b-cell function, fastingand postprandial-glucose, hepatic insulin extraction (HIE) and plasma GLP-1 response) of the subjects influence the GI and II values.
Subjects and methods

Subjects and study design
We recruited male and non-pregnant, non-lactating female subjects aged 18-70 yr (body mass index (BMI) o35 kg/m 2 ) with and without T2DM. Subjects were excluded for any of the following reasons: history of gastrointestinal disease or gastroparesis, liver disease (aspartate transaminase, alanine transaminase, or g-glutamyl transpeptidase42 times upper limit of normal) or kidney disease (creatinine41.2 times upper limit of normal), use of a-glucosidase or lipase inhibitors or insulin, or any acute medical or surgical event requiring hospitalization within 6 months. Subjects without diabetes had fasting glucose o7.0 mmol/l and were divided prospectively into those with normal fasting-serum-insulin (FSI) (healthy control, n ¼ 9, FSI o40 pmol/l), or high-FSI (Hyper [I] , n ¼ 12, FSI X40 pmol/l). Currently, there are no criteria by which an individual could be classified as insulin sensitive or resistant, the rationale for using FSI is that FSI is strongly correlated with insulin resistance measured by euglycemic hyperinsulinemic clamp (Laakso, 1993) . The 40 pmol/l cut-off point was chosen because this represents approximately the 67th percentile for non-diabetic subjects in our laboratory (Wolever et al., 2004) . In previous studies, non-diabetic subjects with FSI 440 pmol/l had significantly greater waist circumference, BMI, homeostasis model assessment insulin sensitivity index, total and low-density lipoprotein cholesterol and triglycerides, and lower highdensity lipoprotein cholesterol than those with FSI o40 pmol/l (Moghaddam et al., 2006) . Ten T2DM patients were recruited, with HbA1C of 7.3 ± 0.3% and duration of diabetes of 7.0 ± 1.0 years (mean ± s.e.m.). Eight patients were on metformin alone, one on metformin and pioglitazone and one on metformin and sulfonylurea. The patients took their usual medication on study days after the fasting blood sample and before starting the test meal. None of the patients had a history of micro-or macro-vascular complications.
The protocol was designed to conform to standard GI testing methodology for subjects with and without diabetes. Subjects were instructed to maintain their usual daily routine and food intake patterns between study days and refrain from exercise on the mornings of the test. After an overnight fast (10-14 h), they came to the Risk Factor Modification Center at St Michael's hospital on eight separate mornings between 0730-0930 hours. Healthy control and hyper [I] subjects had venous blood samples drawn just before and at 15, 30, 45, 60, 90 and 120 min after starting to eat. T2DM had venous blood samples drawn at fasting and at 30, 60, 90, 120 and 180 min after starting to eat. The protocol was reviewed and approved by Research Ethics Boards at the University of Toronto and St Michael's Hospital. All subjects gave written informed consent.
Test foods
Subjects were fed test meals consisting of 50 g availablecarbohydrate (total carbohydrate minus dietary fiber) as 50 g anhydrous-glucose, 50 g sucrose, 71.8 g instant-mashedpotato, 107 g white-bread, 62.5 g polished-rice and 80.6 g pearled-barley. The nutrient composition of the foods was shown in Table 1 . Sugars (glucose þ sucrose) were dissolved in 250 ml water. The test meals were served with a glass of water. Each subject tested glucose 3 times (first, fourth and last tests). The other five test meals were once each in randomized order.
Blood analysis
Venous blood samples for glucose, insulin and C-peptide were collected in BD Vacutainer SST tubes (BD, Franklin Lakes, NJ, USA). Serum glucose was measured by a glucose , with inter-assay coefficient of variation (CV) of 1.9%. Insulin was measured using one-step immunoenzymatic assay (Beckman Access Ultrasensitive Insulin Assay, Beckman Coulter), with inter-assay CV of 2.5-4.3%. Insulin has no cross-reactivity with proinsulin. C-peptide was measured using double antibody competitive radioimmunoassay (Siemens Medical Solutions Diagnostics, Los Angeles, CA, USA), with inter-assay precision of 10% or less.
Venous blood samples for GLP-1 were collected in BD Vacutainer EDTA tubes (BD). The dipeptidyl peptidase (DPP) IV inhibitor (Linco Research, St Charles, MO, USA) was added immediately after collection. Plasma GLP-1 was measured by capturing the active GLP-1 from the sample by a monoclonal antibody (specific binding to the N-terminal region) using GLP-1 (active) ELISA Kit (Linco Research), with inter-assay CV ranges from 1-13%. All the samples were stored at À70 1C before analysis.
Calculations and statistical analysis
The sample size was determined based on previous studies , Wolever, 2003 , with a power of 80% and Po0.05. The AUC for glucose, insulin, C-peptide and GLP-1 were calculated using the trapezoid rule (Wolever et al., 1991) . Hepatic insulin extraction (HIE auc ) was determined by the AUC of C-peptide divided by that of insulin (Polonsky and Rubenstein, 1984) . GI was calculated as the AUC of the test food expressed as a percentage of the mean AUC of three tests of oral-glucose in the same subject (Jenkins et al., 1981) ; the mean of the resulting values was the GI of the food. II was calculated similarly to GI. C-peptide is co-secreted with insulin in equimolar amounts, but is not subjected to hepatic insulin clearance, which varies considerably; thus, C-peptide is regarded as a much better estimate of insulin secretion than levels of insulin itself (Polonsky and Rubenstein, 1984) . Therefore, C-peptide index was also calculated using the same method for GI and II calculation.
The mean glucose and insulin values of the 3 oral-glucosetests were used to calculate oral-glucose-insulin-sensitivity (OGIS) index, which was constructed on established principles of glucose kinetics and insulin action and was validated against the euglycemic-hyperinsulinemic clamp in healthy, obese and T2DM subjects (Mari et al., 2001) .
The b-cell compensation for insulin resistance was estimated using the insulin secretion/insulin resistance (disposition) index derived from OGTT (Abdul-Ghani et al., 2007) , which was shown to be the best predictor of future development of T2DM in subjects with normal glucose tolerance compared with other predictive models such as San Antonio Diabetes Prediction Model (including age, sex, ethnicity, BMI, blood pressure, fasting-plasma-glucose, triglycerides and high-density lipoprotein) and 2-hr plasma glucose concentration (Stern et al., 2002) .
Data were expressed as mean±s.e.m. for normally distributed variables or median (interquartile range) for non-normally distributed variables. Normality was assessed using the Shapiro and Wilk statistic and the normality plots (PROC UNIVARIATE). Skewed variables were log-transformed before analysis. The values of GI, II and C-peptide index were subjected to repeated measures analysis of variance (PROC MIXED) to test for the main effects of food and subject-group and the food Â subject-group interaction. Age, BMI and waist circumference were included in the model as covariates to control their different variables among subjects. Tukey's post hoc test was performed to compare individual means if the main effects or interactions were statistically significant.
The correlations between GI, II and the metabolic indices (insulin sensitivity, b-cell function, HIE, severity of glycemia, and GLP-1 response) were determined by simple linear regressions.
Step-wise multiple regression analysis was used to examine the extent to which the different variables accounted for the variability of GI or II. When GI is the dependent variable, the independent variables are age, BMI, OGIS, disposition index, HIE, and the AUC of glucose and GLP-1. When II is the dependent variable, the independent variables are GI, age, BMI, OGIS, disposition index, HIE, and the AUC of glucose and GLP-1. Collinearity was determined by including variance inflation factor in the model, with variance inflation factor of 5 or 10 and above indicating a multicollinearity problem (O'Brien, 2007) . No collinearity was apparent for the variables included in the regression analysis. All analyses were done using SAS 9.2, (SAS Institute Inc., Cary, NC, USA). Differences were considered significant if two-tailed Po0.05.
Results
T2DM subjects were significantly older and had higher BMI and waist circumference than both healthy control and hyper[I] subjects. Fasting glucose and postprandial glucose responses (glucose AUC) were not significantly different between healthy control and hyper[I] subjects but were significantly higher in T2DM. The intra-individual coefficient of variations (CV) of blood glucose AUC for repeated tests of oral glucose for healthy control, hyper [I] and T2DM subjects are 24±5, 25±3 and 17±3 (mean±s.e.m.), respectively. Fasting insulin was significantly higher in hyper [I] and T2DM than healthy control subjects. Fasting C-peptide increased in a step-wise manner from healthy control to hyper[I] to T2DM (Table 2) . HIE was significantly higher in T2DM than hyper[I] subjects. OGIS and disposition index decreased step-wise from healthy control to hyper[I] to T2DM (Table 2) . Systolic-and diastolic-blood pressure, total cholesterol, triglyceride, total :high-density lipoprotein cholesterol were similar in healthy control and hyper [I] subjects, but were significantly higher in T2DM. Fasting-and postprandial-GLP-1, high-density lipoprotein, low-density lipoprotein and C-reactive protein were not significantly different among the three subject groups (Table 2) .
For GI values, there was neither significant subject-group effects (P ¼ 0.20) nor food Â subject-group interactions (P ¼ 0.26); thus, the GI values were not significantly different among healthy control, hyper [I] and T2DM for any food individually, nor for the mean of all carbohydrate foods (Table 3) . For II values, there was a tendency of significant P represents overall significant differences across groups. P-values were derived from one-way analysis of variance except those for 2-hr postprandial GLP-1 response, hepatic insulin extraction, oral glucose insulin sensitivity and disposition index. 
C-peptide index (%)
Control 100 ± 0 6 5 ± 11 142 ± 18 85 ± 10 45 ± 11 47 ± 7 7 7 ± 7 Hyper [I] 100 ± 0 7 4 ± 9 9 6 ± 12 77 ± 8 7 7 ± 10 44 ± 6 7 4 ± 4 T2DM 100±0 (Table 3) . GI was not related to any of the anthropometric (age and BMI) or metabolic indices (OGIS, HIE, disposition index and GLP-1 response) for each food individually, nor for the mean of all carbohydrate foods (P40.05) (Figure 1 ). Multiple regression analysis using GI as dependent variable and age, BMI, OGIS, disposition index, HIE and AUC of glucose and GLP-1 as independent variables found that none of the variables met the 0.05 significance level for entry into the model.
II was inversely associated with OGIS (r ¼ À0.66, Po0.0001) and positively related to HIE (r ¼ 0.62, P ¼ 0.0002). GI was not related to either OGIS (r ¼ À0.07, P ¼ 0.73) or HIE (r ¼ 0.09, P ¼ 0.65) (Figure 1 ). C-peptide index was not significantly related to OGIS (r ¼ À0.17, P ¼ 0.37) and HIE (r ¼ 0.35, P ¼ 0.057). The GI, II and C-peptide index were not related to either GLP-1 response or disposition index (P40.05). Multiple regression analysis showed that OGIS and HIE together predicted II (II ¼ 106À0.09 Â OGIS þ 2.75 Â HIE), and explained B51% of the variation in II (r 2 ¼ 0.51, Po0.0001). In particular,
OGIS alone explained 43% of the variation in II (r 2 ¼ 0.43,
Po0.001).
GI was not related to any of the markers of the severity of glycemia (P40.05) (Figure 2 ) whereas II was positively associated with fasting-and mean-postprandial-glucose (both r ¼ 0.68, Po0.0001) and glucose AUC (r ¼ 0.46, P ¼ 0.009).
Discussion
This study confirms that the GI values of carbohydrate foods are similar in all subjects regardless of the severity of glycemia or degree of insulin sensitivity. This shows that GI is a property of foods and affirms its clinical utility in a broad population. However, the II values of carbohydrate foods were inversely associated with insulin sensitivity and positively related to the severity of glycemia and HIE, suggesting that II is not solely a property of foods but also depends on the metabolic status of the subjects.
We found that between-subject variation of GI values was not explained by any demographic, anthropometric or metabolic variables. Previous studies have shown that GI values are similar in healthy control vs T2DM (Jenkins et al., 1983) , individuals with type 1 diabetes (T1DM) vs individuals with T2DM (Wolever et al., 1987) , adults vs children with T1DM (Wolever et al., 1988) , T2DM on oral agents vs insulin and T2DM in good vs poor metabolic control . We showed here that the GI values of foods in hyperinsulinemic subjects were similar to those in healthy control and T2DM subjects. Although not unexpected, this is important because GI may be particularly useful for obese and/or insulin resistant subjects to assist with weight management (Ebbeling et al., 2007) and/or the prevention of T2DM (Barclay et al., 2008) and stroke (Oh et al., 2005) . Thus, it is valid to utilize the GI of foods tested in healthy control subjects in the dietary management of hyperinsulinemic/insulin resistant subjects.
The GI values of starchy carbohydrate foods depend on differences in their relative rates of digestion and absorption (that is, the rate of glucose appearance from the gut), (Wolever et al., 1991) which, presumably, do not differ in healthy, hyperinsulinaemic and diabetic subjects. We included sucrose as a test meal because its glycemic response depends, at least in part, on the hepatic metabolism of fructose, which, in turn, may depend on insulin sensitivity. We previously showed that the GI of fruit leather, over 50% of the available-carbohydrate of which consisted of fructose, was inversely related to fasting insulin and to waist circumference (Wolever et al., 2009) . However, the present results are not consistent with this, in that the mean GI of sucrose in hyper[I] subjects was, if anything, slightly higher than in the healthy control. One of the major criticisms of GI is that it does not take into account the concurrent insulin response (Xavier Pi-Sunyer, 2002); thus, some researchers have advocated using II in the treatment of diabetes (Holt et al., 1997 , Bao et al., 2009 ; however, for II to have clinical utility, it must be applicable to a broader population and be similar in all subject groups regardless of their degree of insulin sensitivity and glucose tolerance status. We found that the mean II values of all five carbohydrate foods were higher in T2DM than healthy control and hyperinsulinemic subjects (P ¼ 0.05). Furthermore, II values were inversely related to OGIS and positively related to HIE and the severity of glycemia. In addition, OGIS alone explained 43% of the variation in II. These results suggest that the II of carbohydrate foods vary depending on the metabolic status, thus limiting its clinical utility.
There are physiological basis for the observed higher mean II values of the five carbohydrate foods for T2DM than healthy control and hyperinsulinemic subjects. Glucose is not the only stimulus for insulin secretion, gastrointestinal hormones, mainly GIP and GLP-1 are known to potentiate the stimulatory effect of glucose and mediate postprandial insulin secretion (Meier and Nauck, 2005, Drucker and Nauck, 2006) . In addition, the activity of the entero-insulin axis and HIE all have a role in modulating postprandial insulin concentration. We found that OGIS and b-cell function decreased from healthy control to hyperinsulinemic to T2DM and HIE was much higher in T2DM than healthy control and hyperinsulinemic subjects. These metabolic aberrations, especially reduced b-cell function (less insulin secretion) and increased HIE may reduce plasma insulin response to oral glucose (the reference meal) in T2DM patients; thus other the component of foods (the test meals) on insulin secretion becomes more prominent, which resulted in increased II in T2DM.
Though the mean II value of the carbohydrate foods was higher in T2DM than healthy control and hyperinsulinemic subjects, for each individual food, only in white-bread a significant difference in II was observed. How can the fact that II was correlated with metabolic status (OGIS and the severity of glycemia) be reconciled with the lack of significant difference in II among the subject groups for each individual food (except white-bread)? This may be because II, OGIS and markers of the severity of glycemia are continuous variables, whereas the subject groups (healthy control, hyperinsulinemic and T2DM) are categorical variables. Continuous variables (regression analysis) has greater statistical power than categorical variables (analysis of variance) due to increased precision, a simpler and more informative interpretation of the results, and greater parsimony (Lazic, 2008) ; therefore, categorical variables analysis runs the risk of missing significant effects. It is concluded that the GI of carbohydrate foods is not significantly different among healthy control, hyperinsulinemic and T2DM patients, and the GI is not influenced by subjects' metabolic status. This finding supports the clinical utility of GI in the prevention and management of diabetes. On the contrary, II values were inversely related to OGIS and positively associated with the severity of glycemia and HIE, suggesting that II is not a property of food but is subject dependent. The results suggest that II may have limited clinical utility.
